Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Patient Characteristics
2.2. RNA Extraction and Real-Time Reverse Transcription-Polymerase Chain Reaction
2.3. Cell Culture and Virus Isolation from Clinical Specimens
2.4. Whole-Genome Sequencing of SARS-CoV-2 Isolates
2.5. Phylogenetic Analysis
2.6. Indirect Immunofluorescence Assay
2.7. Statistical Analysis
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kneip, T.; Borsch-Supan, A.; Andersen-Ranberg, K. Social, health and economic impact of the COVID-19 pandemic from a European perspective. Eur. J. Ageing 2022, 19, 789–792. [Google Scholar] [CrossRef]
- Baldelli, S.; Corbellino, M.; Clementi, E.; Cattaneo, D.; Gervasoni, C. Lopinavir/ritonavir in COVID-19 patients: Maybe yes, but at what dose? J. Antimicrob. Chemother. 2020, 75, 2704–2706. [Google Scholar] [CrossRef]
- Hassaniazad, M.; Bazram, A.; Hassanipour, S.; Fathalipour, M. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2020, 21, 886. [Google Scholar] [CrossRef]
- Chen, C.; Fang, J.; Chen, S.; Rajaofera, M.J.N.; Li, X.; Wang, B.; Xia, Q. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 2023, 23, 672. [Google Scholar] [CrossRef]
- Tasavon Gholamhoseini, M.; Yazdi-Feyzabadi, V.; Goudarzi, R.; Mehrolhassani, M.H. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. J. Pharm. Pharm. Sci. 2021, 24, 237–245. [Google Scholar] [CrossRef]
- World Health Organization. Criteria for Releasing COVID-19 Patients from Isolation; World Health Organization: Geneva, Switzerland, 2020; pp. 1–4. Available online: https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-patients-from-isolation (accessed on 8 August 2024).
- Centers for Disease Control and Prevention. Ending Isolation and Precautions for People with COVID-19: Interim Guidance; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2021. Available online: https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/hcp/duration-isolation.html (accessed on 8 August 2024).
- Fontana, L.M.; Villamagna, A.H.; Sikka, M.K.; McGregor, J.C. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. Infect. Control Hosp. Epidemiol. 2021, 42, 659–668. [Google Scholar] [CrossRef]
- Wolfel, R.; Corman, V.M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Muller, M.A.; Niemeyer, D.; Jones, T.C.; Vollmar, P.; Rothe, C.; et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020, 581, 465–469. [Google Scholar] [CrossRef]
- Cvetkovic, R.S.; Goa, K.L. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003, 63, 769–802. [Google Scholar] [CrossRef]
- Group, R.C. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2020, 396, 1345–1352. [Google Scholar]
- Eastman, R.T.; Roth, J.S.; Brimacombe, K.R.; Simeonov, A.; Shen, M.; Patnaik, S.; Hall, M.D. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent. Sci. 2020, 6, 672–683. [Google Scholar] [CrossRef]
- Yan, D.; Ra, O.H.; Yan, B. The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Anim. Dis. 2021, 1, 15. [Google Scholar] [CrossRef]
- Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; et al. Remdesivir for the Treatment of Covid-19-Final Report. N. Engl. J. Med. 2020, 383, 1813–1826. [Google Scholar] [CrossRef]
- Lawrence Panchali, M.J.; Kim, C.M.; Seo, J.W.; Kim, D.Y.; Yun, N.R.; Kim, D.M. SARS-CoV-2 RNAemia and Disease Severity in COVID-19 Patients. Viruses 2023, 15, 1560. [Google Scholar] [CrossRef]
- Chatterjee, S.; Kim, C.M.; Lee, Y.M.; Seo, J.W.; Kim, D.Y.; Yun, N.R.; Kim, D.M. Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea. Sci. Rep. 2022, 12, 11354. [Google Scholar] [CrossRef]
- Lawrence Panchali, M.J.; Oh, H.J.; Lee, Y.M.; Kim, C.M.; Tariq, M.; Seo, J.W.; Kim, D.Y.; Yun, N.R.; Kim, D.M. Accuracy of Real-Time Polymerase Chain Reaction in COVID-19 Patients. Microbiol. Spectr. 2022, 10, e0059121. [Google Scholar] [CrossRef]
- Woloshin, S.; Patel, N.; Kesselheim, A.S. False Negative Tests for SARS-CoV-2 Infection—Challenges and Implications. N. Engl. J. Med. 2020, 383, e38. [Google Scholar] [CrossRef]
- Jia, X.; Xiao, L.; Liu, Y. False negative RT-PCR and false positive antibody tests-Concern and solutions in the diagnosis of COVID-19. J. Infect. 2021, 82, 414–451. [Google Scholar] [CrossRef]
- Cheng, H.Y.; Jian, S.W.; Liu, D.P.; Ng, T.C.; Huang, W.T.; Lin, H.H.; The Taiwan COVID-19 Outbreak Investigation Team. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Intern. Med. 2020, 180, 1156–1163. [Google Scholar] [CrossRef]
- He, X.; Lau, E.H.Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y.C.; Wong, J.Y.; Guan, Y.; Tan, X.; et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 2020, 26, 672–675. [Google Scholar] [CrossRef]
- Jernigan, D.B. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak—United States, February 24, 2020; Morbidity and Mortality Weekly Report; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2020; Volume 69, pp. 216–219. [Google Scholar]
- Choi, B.; Choudhary, M.C.; Regan, J.; Sparks, J.A.; Padera, R.F.; Qiu, X.; Solomon, I.H.; Kuo, H.H.; Boucau, J.; Bowman, K.; et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020, 383, 2291–2293. [Google Scholar] [CrossRef]
- Avanzato, V.A.; Matson, M.J.; Seifert, S.N.; Pryce, R.; Williamson, B.N.; Anzick, S.L.; Barbian, K.; Judson, S.D.; Fischer, E.R.; Martens, C.; et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020, 183, 1901–1912.e9. [Google Scholar] [CrossRef]
- Kang, E.; Lee, S.Y.; Jung, H.; Kim, M.S.; Cho, B.; Kim, Y.S. Operating Protocols of a Community Treatment Center for Isolation of Patients with Coronavirus Disease, South Korea. Emerg. Infect. Dis. 2020, 26, 2329–2337. [Google Scholar] [CrossRef]
- Kang, C.K.; Seong, M.W.; Choi, S.J.; Kim, T.S.; Choe, P.G.; Song, S.H.; Kim, N.J.; Park, W.B.; Oh, M.D. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. Korean J. Intern. Med. 2020, 35, 782–787. [Google Scholar] [CrossRef]
- Gregoire, M.; Le Turnier, P.; Gaborit, B.J.; Veyrac, G.; Lecomte, R.; Boutoille, D.; Canet, E.; Imbert, B.M.; Bellouard, R.; Raffi, F. Lopinavir pharmacokinetics in COVID-19 patients. J. Antimicrob. Chemother. 2020, 75, 2702–2704. [Google Scholar] [CrossRef]
- Marzolini, C.; Stader, F.; Stoeckle, M.; Franzeck, F.; Egli, A.; Bassetti, S.; Hollinger, A.; Osthoff, M.; Weisser, M.; Gebhard, C.E.; et al. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Antimicrob. Agents Chemother. 2020, 64, e01177-20. [Google Scholar] [CrossRef]
- Osborne, V.; Davies, M.; Lane, S.; Evans, A.; Denyer, J.; Dhanda, S.; Roy, D.; Shakir, S. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf. 2020, 43, 809–821. [Google Scholar] [CrossRef]
- Izcovich, A.; Siemieniuk, R.A.; Bartoszko, J.J.; Ge, L.; Zeraatkar, D.; Kum, E.; Qasim, A.; Khamis, A.M.; Rochwerg, B.; Agoritsas, T.; et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: Systematic review and meta-analysis of randomised trials. BMJ Open 2022, 12, e048502. [Google Scholar] [CrossRef]
- Faist, A.; Schloer, S.; Mecate-Zambrano, A.; Janowski, J.; Schreiber, A.; Boergeling, Y.; Conrad, B.C.G.; Kumar, S.; Toebben, L.; Schughart, K.; et al. Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. Antivir. Res. 2023, 209, 105475. [Google Scholar] [CrossRef]
- Kalil, A.C.; Patterson, T.F.; Mehta, A.K.; Tomashek, K.M.; Wolfe, C.R.; Ghazaryan, V.; Marconi, V.C.; Ruiz-Palacios, G.M.; Hsieh, L.; Kline, S.; et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N. Engl. J. Med. 2021, 384, 795–807. [Google Scholar] [CrossRef]
- Schloer, S.; Brunotte, L.; Mecate-Zambrano, A.; Zheng, S.; Tang, J.; Ludwig, S.; Rescher, U. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br. J. Pharmacol. 2021, 178, 2339–2350. [Google Scholar] [CrossRef]
- Kojima, Y.; Nakakubo, S.; Kamada, K.; Yamashita, Y.; Takei, N.; Nakamura, J.; Matsumoto, M.; Horii, H.; Sato, K.; Shima, H.; et al. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. J. Med. Virol. 2022, 94, 5702–5712. [Google Scholar] [CrossRef] [PubMed]
- Schooley, R.T.; Carlin, A.F.; Beadle, J.R.; Valiaeva, N.; Zhang, X.Q.; Clark, A.E.; McMillan, R.E.; Leibel, S.L.; McVicar, R.N.; Xie, J.; et al. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrob. Agents Chemother. 2021, 65, e0115521. [Google Scholar] [CrossRef] [PubMed]
- Brunotte, L.; Zheng, S.; Mecate-Zambrano, A.; Tang, J.; Ludwig, S.; Rescher, U.; Schloer, S. Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. Pharmaceutics 2021, 13, 1400. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, C.-M.; Chung, J.K.; Tamanna, S.; Bang, M.-S.; Tariq, M.; Lee, Y.M.; Seo, J.-W.; Kim, D.Y.; Yun, N.R.; Seo, J.; et al. Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19. Microorganisms 2024, 12, 1696. https://doi.org/10.3390/microorganisms12081696
Kim C-M, Chung JK, Tamanna S, Bang M-S, Tariq M, Lee YM, Seo J-W, Kim DY, Yun NR, Seo J, et al. Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19. Microorganisms. 2024; 12(8):1696. https://doi.org/10.3390/microorganisms12081696
Chicago/Turabian StyleKim, Choon-Mee, Jae Keun Chung, Sadia Tamanna, Mi-Seon Bang, Misbah Tariq, You Mi Lee, Jun-Won Seo, Da Young Kim, Na Ra Yun, Jinjong Seo, and et al. 2024. "Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19" Microorganisms 12, no. 8: 1696. https://doi.org/10.3390/microorganisms12081696